Clinical manifestations in anti-Ro52/SS-A antibody-seropositive patients with Sjögren's syndrome. Issue 4 (2nd October 2021)

• Record Type: Journal Article
• Authors: Nakamura, Hideki; Morimoto, Shimpei; Shimizu, Toshimasa; Takatani, Ayuko; Nishihata, Shin-ya; Kawakami, Atsushi
• Is Part Of: Immunological medicine. Volume 44:Issue 4(2021)
• Page Start: 252
• Page End: 262
• Publication Date: 2021-10-02
• Subjects: Ro60 -- Ro52 -- anti-centromere antibody -- ESSDAI -- Sjögren's syndrome; Immune System Phenomena; Immune System Diseases; Immunology -- Periodicals; Immunology; Periodical; Periodicals; Electronic journals; 571.96
• DOI: 10.1080/25785826.2021.1919342
• Languages: English
• ISSNs: 2578-5826

Abstract

Abstract: Background: The relationship between anti-Ro52/SS-A antibody (anti-Ro52) and the clinical manifestations of Sjögren's syndrome (SS) has not been fully clarified. We determined the clinical factors relevant to SS patients with anti-Ro52. Methods: We conducted a retrospective study of 149 subjects suspicious for SS and 50 healthy control subjects. We analyzed items of the American-European Consensus Group (AECG) criteria and the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). Results: SS was documented in 115 subjects. Anti-Ro52 was observed in 70 SS patients. Anti-Ro52 positivity showed a significantly higher association with anti-Ro60 positivity than with anti-centromere antibody (ACA) positivity ( p < 0.05). Regarding the difference in the anti-Ro52 concentration, we observed six significantly relevant components: two AECG components and four non-AECG components. The anti-Ro52 concentration well-discriminated three clinical factors (ROC AUC >0.75), i.e., ACA seropositivity, ESSDAI score ≥1, and RF, and it moderately discriminated high serum IgG, focus score ≥1, and anti-La/SS-B antibody seropositivity (ROC AUC >0.7). A linear relationship between the ESSDAI score and the anti-Ro52 concentration was observed. Conclusion: A significant association between clinical factors (including the ESSDAI) and the anti-Ro52 concentration were revealed. Anti-Ro52 was more highly associated with anti-Ro60 positivity than with ACA positivity.